Table 2. Serious Side Effects During the First 16 Weeks of the Study
Serious side Tezepelumab Tezepelumab Tezepelumab Placebo
effect 210 mg Q4W 280 mg Q2W 420 mg Q2W Q2W
(59 participants) (58 participants) (70 participants) (63 participants)
Inflammation
of the tubes 1 participant 0 participants 0 participants 0 participants
going to the (2%) (0%) (0%) (0%)
lungs
Inflammation
of the skin 1 participant 0 participants 0 participants 0 participants
with red, itchy (2%) (0%) (0%) (0%)
patches
Inflammation
of the skin 1 participant 0 participants 0 participants 0 participants
with itchiness (2%) (0%) (0%) (0%)
and blisters
High blood 0 participants 0 participants 1 participant 0 participants
pressure (0%) (0%) (1%) (0%)
The table below shows the non-serious side effects that occurred in at least 5% of
participants (or about 5 out of 100).
11